- Home
- CODX vs NXTC Comparison
CODX vs NXTC Comparison
Compare CODX & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODX
- NXTC
- Stock Information
- Founded
- CODX 2013
- NXTC 2015
- Country
- CODX United States
- NXTC United States
- Employees
- CODX N/A
- NXTC N/A
- Industry
- CODX Medical/Dental Instruments
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- CODX Health Care
- NXTC Health Care
- Exchange
- CODX Nasdaq
- NXTC Nasdaq
- Market Cap
- CODX 22.0M
- NXTC 21.6M
- IPO Year
- CODX 2017
- NXTC 2019
- Fundamental
- Price
- CODX $0.71
- NXTC $0.72
- Analyst Decision
- CODX Hold
- NXTC Strong Buy
- Analyst Count
- CODX 1
- NXTC 2
- Target Price
- CODX $1.50
- NXTC $4.00
- AVG Volume (30 Days)
- CODX 139.9K
- NXTC 62.2K
- Earning Date
- CODX 03-13-2025
- NXTC 03-20-2025
- Dividend Yield
- CODX N/A
- NXTC N/A
- EPS Growth
- CODX N/A
- NXTC N/A
- EPS
- CODX N/A
- NXTC N/A
- Revenue
- CODX $7,321,012.00
- NXTC N/A
- Revenue This Year
- CODX N/A
- NXTC N/A
- Revenue Next Year
- CODX N/A
- NXTC N/A
- P/E Ratio
- CODX N/A
- NXTC N/A
- Revenue Growth
- CODX 57.16
- NXTC N/A
- 52 Week Low
- CODX $0.65
- NXTC $0.66
- 52 Week High
- CODX $2.23
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- CODX 43.93
- NXTC 40.34
- Support Level
- CODX $0.69
- NXTC $0.66
- Resistance Level
- CODX $0.73
- NXTC $0.79
- Average True Range (ATR)
- CODX 0.04
- NXTC 0.06
- MACD
- CODX 0.00
- NXTC 0.00
- Stochastic Oscillator
- CODX 42.31
- NXTC 42.21
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.